Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -91.8%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $416687 | $1.7B | $1M | $105M | $230M | — | — |
| Enterprise Value | $-4641038 | $-5774314 | $1.7B | $-1598510 | $102M | $218M | — | — |
| P/E Ratio → | -0.07 | — | — | — | — | — | — | — |
| P/S Ratio | 4.06 | 1.09 | 2170.01 | 1.21 | 57.19 | 197.61 | — | — |
| P/B Ratio | 0.01 | 0.02 | 667.72 | 0.40 | 28.99 | 17.36 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -15.12 | 2167.45 | -1.36 | 55.56 | 187.09 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -1.3% | -1.3% | 0.3% | 24.4% | 16.3% | -11.1% | -26.2% | -68.8% |
| Operating Margin | -2067.5% | -2067.5% | -725.8% | -701.1% | -548.8% | -483.0% | -372.6% | -867.4% |
| Net Profit Margin | -2324.1% | -2324.1% | -725.0% | -701.0% | -548.7% | -728.5% | -423.1% | -987.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -91.8% | -91.8% | -185.0% | -228.7% | -119.5% | -140.5% | -609.5% | -174.9% |
| ROA | -51.6% | -51.6% | -142.0% | -147.5% | -95.9% | -102.5% | -159.8% | -137.2% |
| ROIC | -106.4% | -106.4% | -781.2% | -1033.2% | -919.1% | -3339.1% | — | -4553.8% |
| ROCE | -47.2% | -47.2% | -180.0% | -208.8% | -112.5% | -80.0% | -243.9% | -153.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.38 | 0.38 | — | 0.10 | 0.15 | 0.05 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.37 | -0.79 | -0.85 | -0.82 | -0.92 | — | -0.97 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -53.75 | -53.75 | — | — | — | -3.66 | -7.60 | -8.36 |
Net cash position: cash ($13M) exceeds total debt ($6M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 20.13 | 20.13 | 9.70 | 3.32 | 2.51 | 11.72 | 1.17 | 4.55 |
| Quick Ratio | 20.13 | 20.13 | 8.53 | 2.78 | 2.05 | 11.37 | 0.99 | 3.83 |
| Cash Ratio | 19.57 | 19.57 | 7.36 | 2.42 | 1.87 | 10.64 | 0.82 | 3.54 |
| Asset Turnover | — | 0.01 | 0.28 | 0.23 | 0.31 | 0.08 | 0.56 | 0.14 |
| Inventory Turnover | — | — | 2.44 | 1.18 | 1.79 | 3.02 | 4.50 | 1.49 |
| Days Sales Outstanding | — | 0.96 | 32.29 | 54.01 | 21.23 | 28.80 | 22.07 | 11.30 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $287370 | $287M | $46650 | $96730 | $34933 | $23032 | $23000 |
Capital structure insolvency risk
According to recent market data, TIVC trades at a price-to-sales ratio of 4.06, which appears significantly detached from the company's negative gross margins and contracting revenue trajectory, suggesting investors may be pricing the equity as a speculative R&D option rather than a viable commercial enterprise.
The lack of a positive forward P/E or EV/EBITDA multiple reflects the absence of sustainable earnings, forcing the market to rely on book value metrics that are themselves potentially inflated. This valuation premium warrants caution, as it implies an expectation of a strategic pivot or acquisition that remains unproven by current operational output.
Based on reported figures, TIVC's ROIC has consistently languished in deep negative territory, reaching -26.8% in 2026Q1, which indicates that the company is currently destroying shareholder value with every dollar of capital deployed into its core medical device operations.
The persistent decay in returns on invested capital suggests that the company's cost structure is fundamentally misaligned with its revenue-generating capacity. Without a drastic improvement in margins or a reduction in capital intensity, the company appears unable to achieve the compounding returns necessary to justify its current asset base.
As reported in financial statements, the company's cash conversion cycle has exhibited extreme volatility, swinging from 192 days in 2025Q1 to -55 days in 2025Q3, reflecting significant challenges in managing inventory levels and collecting payments from its retail distribution partners.
The erratic nature of the cash conversion cycle suggests that TIVC lacks a predictable operational rhythm, likely exacerbated by the high return rates inherent in its consumer-facing hardware model. Investors should monitor these fluctuations as they indicate potential bottlenecks in the supply chain and a lack of leverage over retail channels.
According to recent SEC filings, TIVC's debt-to-equity ratio surged to 1.54 in 2026Q1, marking a significant departure from the near-zero leverage maintained in previous periods and signaling an increased reliance on external financing to sustain its ongoing operational cash burn.
The rapid accumulation of debt in the face of contracting revenue suggests that the company is exhausting its balance sheet flexibility to fund losses. This trend increases the risk of future dilutive equity raises or restrictive covenant triggers, which may further impair shareholder value in the near term.
The most commonly misapplied metric for TIVC is the price-to-sales ratio, which obscures the company's negative gross margins and fails to account for the fact that each incremental sale may currently be value-destructive rather than value-accretive to the firm's overall financial health.
Analysts should instead focus on unit-level contribution margins and the cash burn rate relative to the remaining liquidity runway. Relying on revenue multiples in a business model where the cost of goods sold exceeds net revenue leads to a dangerous overestimation of the company's intrinsic value.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TIVC stock.
Tivic Health Systems, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Tivic Health Systems, Inc.'s return on equity (ROE) is -91.8%. The historical average is -156.7%.
Based on historical data, Tivic Health Systems, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Tivic Health Systems, Inc. has -1.3% gross margin and -2067.5% operating margin.